News | November 05, 2024
Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Aims to achieve CDMO sales of US$ 400 million by 2028
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Stable profits, low leverage to keep credit profiles comfortable
Subscribe To Our Newsletter & Stay Updated
